

Donald F. Weaver, M.D., Ph.D., is the Director and Senior Scientist at the Krembil Research Institute within the University Health Network of the University of Toronto.

As a leading expert in computer-aided drug design, his medicinal chemistry work researches applications to neurodegenerative disorders.

Weaver is applying his research design strategy to a variety of disorders including Alzheimer's disease, other dementias, epilepsy and stroke. His contributions to Alzheimer's research specifically include designing brain-penetrant compounds that block neuronal degradation.

His work in the fields of quantum and molecular mechanics contributed to his founding of several biotech companies, including Neurochem Inc. and Treventis Corporation. At Neurochem, Weaver co-discovered and co-developed Alzhemed, the first "disease modifying" anti-aggregation drug to reach phase 3 human clinical trials for the treatment of Alzheimer's disease.

In addition to work on both basic and translational science, Weaver emphasizes the importance of addressing the growing need for new innovative therapeutics for a variety of brain disorders.

Weaver has published more than 150 peer-reviewed articles and holds more than 70 patents. He is the recipient of numerous awards, honors and grants, including the 2011 Jonas Salk Award, the 2010 Bantrel Award and the 2009 Prix Galien, which was awarded for his research into the cause of Alzheimer's. Weaver received his M.D. and Ph.D. degrees from Queen's University in Ontario, Canada.